Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Polypeptide and application and pharmaceutical composition thereof

A composition and drug technology, applied in the field of biomedicine, can solve the problems affecting the quality of life of children, unclear pathogenesis, and high mortality, and achieve the effects of restoring intestinal tissue shape, structure integrity, and reducing intestinal damage.

Active Publication Date: 2022-02-08
WUXI CHILDRENS HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] NEC has a long course of disease and poor prognosis, and the surviving children are often accompanied by various sequelae such as short bowel syndrome, intestinal stenosis, and long-term neurodevelopmental disorders, which not only seriously affect the quality of life of the children, but also bring great harm to the family and society. heavy burden
Because the exact etiology and pathogenesis are unclear, there are still no effective clinical measures for the prevention and treatment of NEC disease. At present, antibiotics, supportive treatment including nasogastric tube suction, intravenous rehydration, total parenteral nutrition, and late surgery are the mainstays. Mainly, but the postoperative mortality rate of children is still as high as 50%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide and application and pharmaceutical composition thereof
  • Polypeptide and application and pharmaceutical composition thereof
  • Polypeptide and application and pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0085] Effect of embodiment 1PP1 on NEC model intestinal epithelial cells

[0086] 1. Experimental materials

[0087] FHC cells: Fetal Human Colon Epithelial Cell, human intestinal epithelial cells, purchased from ATCC (CRL-1831).

[0088] 2. Experimental grouping

[0089] Set CON group, NEC group, NEC+Scr (scrambled polypeptide sequence) group and NEC+PP1 group.

[0090] 3. Experimental method

[0091] 3.1 Cell Culture

[0092] FHC cells at 37°C, 5% CO 2 Cultivate under conditions until the growth density is 80%-90%, to obtain FHC cell culture fluid.

[0093] 3.2 Construction of NEC cell model

[0094] CON group: No lipopolysaccharide (LPS) induction treatment was applied to the FHC cell culture medium;

[0095] NEC group: adding LPS (100 μg / mL) to the FHC cell culture medium to induce for 3 hours, and constructing the NEC cell model;

[0096] NEC+Scr group: add control peptide Scr (100 μM) to FHC cell culture medium, add LPS (100 μg / mL) after 1 hour to induce 3 h; ...

Embodiment 2

[0138] The impact of embodiment 2PP1 on NEC animal model

[0139] 1. Experimental animals

[0140] SPF-grade newborn SD rats and their mothers were purchased from the Animal Experiment Center of Nanjing Medical University, and they were raised in the Experimental Animal Center of Nanjing Medical University under the conditions of alternating light and dark every 12 hours, room temperature 24°C, and humidity 50%.

[0141] 2. Experimental grouping

[0142] Set CON group, NEC group, NEC+Scr group and NEC+PP1 group.

[0143] 3. Experimental method

[0144] 3.1 Construction of NEC animal model

[0145] Newborn SD rats weighing 6-9g within 24 hours of birth were randomly divided into four groups:

[0146] CON group: newborn SD rats were caged with their mothers and breast-fed;

[0147] NEC group: Neonatal SD rats were asphyxiated once every 8 hours (conditions: 5% O 2 , 95%N 2 , 5min), within 2min after the end of each hypoxia, hyperosmotic milk (Wyeth 1 stage milk powder: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
emission peakaaaaaaaaaa
Login to View More

Abstract

The invention relates to a polypeptide and application and a pharmaceutical composition thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO. 1. The polypeptide provided by the invention has biological activity for preventing and treating neonatal necrotizing enterocolitis, and the biological activity is verified on an NEC cell model and an NEC animal model. The polypeptide provided by the invention can be used for preparing medicines for resisting neonatal necrotizing enterocolitis, and provides more prevention and treatment means for clinically treating neonatal necrotizing enterocolitis.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a polypeptide and its application and pharmaceutical composition. Background technique [0002] Necrotizing enterocolitis (Necrotizing enterocolitis, NEC) is an acquired disease, which is a disease caused by intestinal mucosal damage caused by various reasons, resulting in ischemia and hypoxia, resulting in diffuse or local necrosis of the small intestine and colon . NEC disease mainly occurs in premature infants or sick newborns, most of which occur 2 to 12 days after birth. The pathogenesis is still unclear, and it is generally believed that premature infants are due to less gastric acid secretion, poor gastrointestinal motility, and low protease activity. , high permeability of the digestive tract mucosa, low digestion and absorption and local immune response, so infection, intestinal wall ischemia and hypoxia, inappropriate intestinal feeding and other pathogenic factors can easil...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/06A61P1/00A61K45/06A61K38/08
CPCC07K7/06A61P1/00A61K45/06A61K38/08A61K38/00Y02A50/30
Inventor 章乐李沄卜超志夏静尹安雯李征瀛金未来
Owner WUXI CHILDRENS HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com